Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ottobock on its acquisition of Exoneural Network AB
Mandate

Vinge advises Ottobock on its acquisition of Exoneural Network AB

January 25, 2021 Employment and Benefits IT, Telecommunications and Outsourcing M&A Corporate Commercial Corporate Crime & Compliance

Vinge advises Ottobock, a portfolio company to EQT, on its acquisition of Exoneural Network AB a Swedish startup that has developed the so called Exopulse Mollii Suit.

The suit covers the entire body and uses electrostimulation to relax tense or spastic muscles which can improve the mobility for people with spastic diseases. Ottobock is an international medtech company and the acquisition is a step towards the expansion of its portfolio for promising neuro-orthotics.

Vinge’s team consisted of, among others, partner Christina Kokko, associates Stina Bengtsson, Jesper Lindvall and Annie Fällström (M&A), Sara Strandberg and Carl Östlund (Employment), Stojan Arnerstål och Sofia Bergenstråhle (IP), Mika Jordan (IT & GDPR), Christoffer Nordin (Regulatory) Fredrika Hjelmberg and Carla Zachariasson (Commercial Agreements) Tove Lövgren Frisk (Compliance) and Carl Bruneheim (Project assistant).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026